Glenmark Pharmaceuticals is currently trading at Rs. 541.75, up by 132.65 points or 32.42% from its previous closing of Rs. 409.10 on the BSE.
The scrip opened at Rs. 450.00 and has touched a high and low of Rs. 572.70 and Rs. 450.00 respectively. So far 3354299 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 572.70 on 22-Jun-2019 and a 52 week low of Rs. 168.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 572.70 and Rs. 387.25 respectively. The current market cap of the company is Rs. 15321.73 crore.
The promoters holding in the company stood at 46.62%, while Institutions and Non-Institutions held 35.26% and 18.12% respectively.
Glenmark Pharmaceuticals has received the manufacturing and marketing approval from India’s drug regulator to launch the oral antiviral drug Favipiravir (FabiFlu) for the treatment of mild to moderate COVID-19 patients in India.
This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak. It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.
Glenmark Pharmaceuticals (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
